-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $112

Benzinga·07/29/2025 11:43:03
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $70 to $112.